Special
National Pharmaceutical Council Appoints John M. O’Brien as President and CEO (4/2, National Pharmaceutical Council) “...‘John brings to NPC a keen understanding of the issues facing both health care and the innovative biopharmaceutical industry, as well as a deep understanding of the important role NPC plays within the broader health care environment,’ said Michael L. Ryan, Pharm.D., chair of NPC’s Board of Directors and senior vice president, Worldwide Value, Access, Pricing and Health Economics and Outcomes Research, Bristol Myers Squibb...‘I am honored to welcome John to the executive leadership team at NPC. His proven track record in the national health policy community and broad experience across health care will be central to NPC’s ongoing pursuit of sound evidence and forward-looking thinking,’ [NPC’s Robert Dubois, M.D., Ph.D.] said.” Full
FDA Lets Moderna Boost Vial Doses (4/2, Susannah Luthi, Politico Pulse) reports “...John O’Brien will be the new president and CEO of the National Pharmaceutical Council, Adam Cancryn reports. O’Brien, who officially takes over on June 1, spent two-and-a-half years at the Trump health department, including as senior adviser for drug pricing reform to then-Secretary Alex Azar, before departing in 2019.” Full
Articles
Comparing Radiation Treatments for Managing Localized, Intermediate-Risk Prostate Cancer (4/1, Marta Rybczynski, Journal of Clinical Pathways) reports “A recent study comparing brachytherapy, dose-escalated external beam radiotherapy, and stereotactic body radiation therapy, argues against the move toward hypofractionation for treating localized, intermediate-risk prostate cancer, suggesting that brachytherapy is the most appropriate management strategy in delivering value-based care.” Full
Events
Increasing Vaccine Confidence among Long-Term Care Workers: Expedited COVID-19 PFA -- Applicant Town Hall April 19, 2021 12:00 - 1:00PM EDT PCORI